0001181431-13-033365.txt : 20130607
0001181431-13-033365.hdr.sgml : 20130607
20130607060036
ACCESSION NUMBER: 0001181431-13-033365
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130604
FILED AS OF DATE: 20130607
DATE AS OF CHANGE: 20130607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 930797222
STATE OF INCORPORATION: OR
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-444-8424
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 7
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Christopher Nishan Garabedian
CENTRAL INDEX KEY: 0001492604
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 13898840
MAIL ADDRESS:
STREET 1: 333 RIVER STREET
STREET 2: #303
CITY: HOBOKEN
STATE: NJ
ZIP: 07030
4
1
rrd382735.xml
FORM 4
X0306
4
2013-06-04
0
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001492604
Christopher Nishan Garabedian
215 FIRST STREET, SUITE 7
CAMBRIDGE
MA
02412
1
1
0
0
President and CEO
Incentive Stock Option (right to buy)
34.9200
2013-06-04
4
A
0
2863
0
A
2023-06-04
Common Stock
2863
2863
D
Non-Qualified Stock Option (right to buy)
34.9200
2013-06-04
4
A
0
182137
0
A
2023-06-04
Common Stock
182137
182137
D
Non-Qualified Stock Option (right to buy)
34.9200
2013-06-04
4
A
0
185000
0
A
2023-06-04
Common Stock
185000
185000
D
This option is exercisable at the rate of 25% of the shares on the first anniversary of the date of grant and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on the fourth anniversary of the date of grant.
In the event of the achievement of certain performance milestones prior to January 1, 2017, the shares subject to the option will vest and become exercisable with respect to 1/4th of the total number of shares subject to the option on June 4, 2014 and 1/48th of the original number of shares subject to the option monthly thereafter, subject to continued service with the Issuer.
On June 6, 2013, Sarepta Therapeutics, Inc., a Delaware corporation, became the successor of Sarepta Therapeutics, Inc., an Oregon corporation, pursuant to a merger. The merger had the effect of changing the state of incorporation of Sarepta Therapeutics, Inc. from Oregon to Delaware, but did not alter the proportionate interests of security holders.
By: David Tyronne Howton For: Christopher Nishan Garabedian
2013-06-06